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We welcome the renewed interest in the therapeutic potential of psychedelic 
compounds. In their recent editorial, Sessa and Johnson1 echo the fervent research 
climate surrounding psychedelics spanning the 1950s and 60s. They suggest that 
psychedelics may cause prolonged changes in subjects’ personalities and attitudes 
following mystical-spiritual experiences. This unique and exciting potential 
mechanism of action certainly warrants the current renaissance in psychedelic 
research, and has important implications for study design and subject selection. As we 
move towards re-exploring the clinical applications of psychedelics, however, we 
must appreciate that the phenomenology of the psychedelic experience is likely to 
depend not only on a drug’s pharmacodynamic properties, but also on the makeup of 
the subject (‘set’) and the environmental context (‘setting’) in which the drug is 
administered.  
  
Recent work suggests that the potential importance of ‘set’ in the psychedelic 
experience should not be overlooked. Hallucinogenic compounds act via the 
serotonergic 5-HT2A receptor to effect experience and behaviour. Genetic and 
neuroimaging evidence suggests that inter-subject differences in serotonergic 
neurotransmission relate to personality differences and vulnerability to psychiatric 
illness.2 Relatedly, research with hallucinogenic compounds has reported sustained 
changes in personality traits and behaviour.3 Moreover, anecdotal reports suggest that 
the quality of the psychedelic experience (whether the ‘trip’ is ‘good’ or ‘bad’) has 
some connection to the attitude and particular psychological landscape of the person 
taking the drug.4 Finally, a closer look at the psychological profile of subjects who 
volunteer for psychedelic research studies reveals that they may not be representative 
of the general population, and in particular may be more ‘open’ to new experiences, 
limiting the generalisability of study findings to clinical samples.3 The effect of a 
hallucinogenic compound on an individual’s experience, therefore, may be influenced 
by the individual’s neurobiological and psychological composition. 
 
The quality of the psychedelic experience is also inextricably linked to the 
environmental and social ‘setting’. In the late 1960s several studies strove to isolate 
the hallucinogenic effect of a drug from external influences, such as the use of 
concomitant therapy.5 Their efforts generated less promising results than studies that, 
by design, emphasised the importance of the ‘setting’.5 As an illustrative example, 
one study found sensory deprivation to be antagonistic to the ‘LSD experience’.6 
Consequently, the relationship between the psychedelic experience and the ‘setting’ 
must be considered in experimental design. Even a structured test or interview can 
radically alter the resulting phenomenology.6  
  
We propose that a fruitful research programme investigating the therapeutic potential 
of psychedelic compounds must take the complex interaction between ‘set’ and 
‘setting’ into account in its subject recruitment and study design. By acknowledging 
this association future research will be in a position to understand the full breadth of 
the psychedelic experience and its potential clinical applications. Although practically 
challenging, such a comprehensive approach will allow us to re-examine the perhaps 
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